RECLAIM
BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 34 patients (estimated)
- Sponsors
- Medical College of Wisconsin
- Tags
- Bispecific Antibody, Bispecific T Cell Engager (BiTE), CD3, B-Cell Maturation Antigen (BCMA), Post-CAR T
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2137
- NCT Identifier
- NCT07009899
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.